Press Releases

2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

2012
Dec 2012 | Download as pdf

Sandalwood giant can smell big dollars in warts more

Dec 2012 | Download as pdf

ViroXis Corporation Announces expanded board of directors and advisors more

Dec 2012 | Download as pdf

ITClamp Hemorrhage Control System from Innovative Trauma Care more

Dec 2012 | Download as pdf

ViroXis Corporation Initiates Phase II Clinical Trial of Novel Botanical Topical Treatment for HPV Skin Warts more

Oct 2012 | Download as pdf

Vidacare Corp. aims to ease that pain with the OnControl Bone Marrow System. The Bronze winner of The Wall Street Journal's Technology Innovation Awards, and winner of the Medical-Devices category, the product allows doctors to more quickly and precisely take samples from inside the bone more

Oct 2012 | Download as pdf

Merger Results in Leading Company for Oncolytic Adenoviruses for Cancer

HOUSTON, TX– October 23, 2012 – DNAtrix, Inc., the Houston-based biotechnology company developing targeted adenovirus-based oncolytic virus products, announced today a merger with VectorLogics, Inc. (VLI), a company with a complementary intellectual property portfolio developing products for ovarian cancer. The merged company will retain the name DNAtrix and continue to develop its lead cancer product, DNX-2401, which is in clinical testing at the University of Texas M.D. Anderson Cancer Center for treating high grade brain tumors.

Dr. Imre Kovesdi, Ph.D., chief executive officer of VLI, and Dr. David T. Curiel, M.D., Ph.D., chief scientific officer and founder of VLI, will join the merged company as chief scientific officer and member of the Scientific Advisory Board, respectively. “We are extremely pleased to join forces with Drs. Curiel and Kovesdi in this important effort,” stated Frank Tufaro, Ph.D., chief executive officer of the merged company. “The merger makes strategic sense, and we are now a much stronger company in all respects.”

“As an inventor of VLI’s adenoviral technology,” stated Dr. Curiel. “I am very pleased to be able to work with the DNAtrix team in turning these discoveries into new cancer therapies. This is a win-win for both companies.” back

Sept 2012 | Download as pdf

Innovative Trauma Care (ITC) has received regulatory approval from Health Canada for commercial sale of its first product, the IT Clamp™ more

Sept 2012 | Download as pdf

BiO2 Medical, Inc and R&D and manufacturing operations in Golden, Colorado, has recently secured $12M in Series C funding more

Sept 2012 | Download as pdf

ENTrigue Surgical Announces Sinus Surgery Collaboration with fiagon GmbH more

June 2012 | Download as pdf

Soluble Therapeutics, Inc. Awarded ~$1MM NIH Grant for Continued Development of the HSC Technology for Protein Formulation more

June 2012 | Download as pdf

Vidacare Corporation Creates New Medical Director of Clinical Affairs Position for Intraosseous Vascular Access Division more

May 2012 | Download as pdf

BiO2 Medical Granted CE Mark for the Angel™ Catheter, the First IVC Filter with a Prophylactic Use Indication more

April 2012 | Download as pdf

NMP Neuwirth Medical Products GmbH signs an exclusive distribution partnership for the Ventera, MediENT, ENTact, Synaero, and SerpENT in Germany

March 2012 | Download as pdf

ENTrigue Surgical participates in the first Global Update on FESS, The Sinuses, and The Nose in Vienna, Austria

March 2012 | Download as pdf

BiO2 Medical Announces First in Man Clinical Study more

March 2012 | Download as pdf

BiO2 Medical Secures Series B Round Funding more

Jan 2012 | Download as pdf

Study Finds Intraosseous Infusion is Equivalent to Intravenous Infusion During Therapeutic Hypothermia more

Jan 2012 | Download as pdf

Vidacare Corporation to Sponsor 2012 British Journal of Nursing Haematology Award Category more